glp 1 shortage update Novo Nordisk's semaglutide officially concludes in the US, spelling major threat for weight loss drug compounders GLP-1 Pipeline Update: August 2025

14 May Who Cant Take GLP-1 Drugs

[1] [2] The question of treatment duration is complex because obesity is recognized as a chronic disease requiring long-term management rather than a temporary condition with a definitive cure

Genuine, licensed medication from authorised supply chains

A pharmacovigilance analysis using data from the FDA's Adverse Event Reporting System identified a statistically significant association between GLP-1 RAs and the onset of headache, with a reporting odds ratio (ROR) of 1.74, and migraine (ROR: 1.28), suggesting that these symptoms can develop regardless of pre-existing headache diagnoses

Those exploring the combination of semaglutide with B12 are already thinking along the right lines about nutritional support during therapy

Will insurance cover glutathione